$MRNA News

Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth Story

JP Morgan Maintains Underweight on Moderna, Raises Price Target to $77

Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $120

UBS Maintains Neutral on Moderna, Raises Price Target to $150

Moderna, Merck cancer vaccine: William Blair's Myles Minter on what the breakthrough could mean

Wall Street Breakfast Podcast: Moderna's $44B Booster

Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $89

William Blair Upgrades Moderna to Outperform

Moderna: Stock Surging On Cancer 'Vaccine' Breakthrough, I See More Volatility Ahead

Moderna and Merck shares surge

FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax

Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market

Moderna: I'm Still On Sell, But Here's What Would Change My Mind

Moderna (MRNA) Q2 2026 Earnings Call Transcript

Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

Moderna (MRNA) Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine

Moderna (MRNA) Wins Flu Vaccine Approval, Is It Fully Priced?

Moderna Dives Despite Hard-Fought FDA Win; Will Its Sprint Restart?